National Center for Complementary & Integrative Health; Notice of Closed Meeting, 46895 [2024-11851]
Download as PDF
<![CDATA[
46895
Federal Register / Vol. 89, No. 105 / Thursday, May 30, 2024 / Notices
Advocate Forms at the National Cancer
Institute (NCI)’’ for an additional three
years of data collection. The Office of
Advocacy Relations (OAR) disseminates
cancer-related information to a variety
of stakeholders, seeks input and
feedback, and facilitates collaboration to
advance NCI’s authorized programs. It is
beneficial for NCI, through the OAR, to
pretest strategies, concepts, activities
and materials while they are under
development. Additionally,
administrative forms are a necessary
part of collecting demographic
information and areas of interest for
advocates. Since OAR is responsible for
matching advocates to NCI programs
and initiatives across the cancer
continuum, it is necessary to measure
the satisfaction of both internal and
external stakeholders with this
collaboration. This customer satisfaction
research helps ensure the relevance,
utility, and appropriateness of the many
initiatives and products that OAR and
NCI produce. Past research has enabled
OAR to monitor stakeholder trends,
design and develop materials based on
user feedback, assess the impact of
activities, and improve service delivery.
Primary users are internal with some
advocates providing contact
information, demographics and prior
advocacy experience via a link provided
to them to input their data.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
17.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses per
respondent
Advocates Survey ..............................
Requestor Survey ...............................
Profile Completion ..............................
6
6
30
1
1
1
5/60
5/60
30/60
1
1
15
.............................................................
....................
42
........................
17
Type of respondent
Form name
Individuals ...........................................
Individuals ...........................................
Individuals ...........................................
Total .............................................
Dated: May 24, 2024
Diane Kreinbrink,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.
[FR Doc. 2024–11897 Filed 5–29–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
ddrumheller on DSK120RN23PROD with NOTICES1
National Center for Complementary &
Integrative Health; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Integrative Health
Special Emphasis Panel; Clinical and Data
Coordinating Center Applications for NCCIH
Multi-Site Clinical Trials of Mind and Body
Interventions.
Date: June 27, 2024.
Time: 9:30 a.m. to 1:30 p.m.
VerDate Sep<11>2014
20:03 May 29, 2024
Jkt 262001
Agenda: To review and evaluate grant
applications.
Place: National Center for Complementary
and Integrative, Democracy II, 6707
Democracy Blvd., Bethesda, MD 20892.
Contact Person: Mei Qin, MD, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, Division of Extramural Activities,
NCCIH/NIH, 6707 Democracy Blvd., Suite
401, Bethesda, MD 20892, mei.qin@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: May 23, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–11851 Filed 5–29–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. to achieve
expeditious commercialization of
results of federally-funded research and
development.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
SUMMARY:
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
Average time
per response
( in hours)
Total annual
burden hour
by emailing the licensing contact
Michael Shmilovich, Esq, MS, CLP;
301–435–5019; michael.shmilovich@
nih.gov at the National Heart, Lung, and
Blood, Office of Technology Transfer
and Development Office of Technology
Transfer, 31 Center Drive, Room 4A25,
MSC2479, Bethesda, MD 20892–2479. A
signed Confidential Disclosure
Agreement may be required to receive
any unpublished information.
SUPPLEMENTARY INFORMATION: This
notice is in accordance with 35 U.S.C.
209 and 37 CFR part 404. Technology
description follows.
Next generation MRI platform Signal
Amplification by Reversible Exchange
(SABRE) hyperpolarization:
Hyperpolarized magnetic resonance
imaging (MRI) is an emerging molecular
imaging method for metabolic imaging
for detecting cancer, cardiovascular
disease, stroke, and traumatic brain
injury and monitoring therapy with no
Gadolinium or Iron. Available for
licensing and commercial development
is a patent estate covering a
perfluorinated single amplification by
reversible exchange (SABRE) catalyst for
generating MRI agents that includes a dblock element and a perfluorinated
ligand hyperpolarized substrate
comprising a 1⁄2 spin nucleus or nuclei
using the perfluorinated SABRE
catalysts, and isolating the resulting
hyperpolarized substrate for
administration. The invention also
provides methods for separating a
hyperpolarized substrate from the
SABRE catalyst and/or hyperpolarized
SABRE catalyst complex containing a
E:\FR\FM\30MYN1.SGM
30MYN1
]]>Agencies
[Federal Register Volume 89, Number 105 (Thursday, May 30, 2024)]
[Notices]
[Page 46895]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-11851]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center for Complementary & Integrative Health; Notice of
Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center for Complementary and
Integrative Health Special Emphasis Panel; Clinical and Data
Coordinating Center Applications for NCCIH Multi-Site Clinical
Trials of Mind and Body Interventions.
Date: June 27, 2024.
Time: 9:30 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Center for Complementary and Integrative,
Democracy II, 6707 Democracy Blvd., Bethesda, MD 20892.
Contact Person: Mei Qin, MD, Ph.D., Scientific Review Officer,
Office of Scientific Review, Division of Extramural Activities,
NCCIH/NIH, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.213,
Research and Training in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: May 23, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee
Policy.
[FR Doc. 2024-11851 Filed 5-29-24; 8:45 am]
BILLING CODE 4140-01-P
